HCW BIOLOGICS INC. - COMMON STOCK

HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

03 фев 2025 07:15:07 Источник Nasdaq GlobeNewswire

HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

15 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

23 дек 2024 08:10:13 Источник Nasdaq GlobeNewswire

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

18 ноя 2024 21:27:48 Источник Nasdaq GlobeNewswire

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

18 ноя 2024 07:01:10 Источник Nasdaq GlobeNewswire

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

14 ноя 2024 16:40:41 Источник Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

23 авг 2024 16:30:36 Источник Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

14 авг 2024 16:35:03 Источник Nasdaq GlobeNewswire

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

15 май 2024 16:39:10 Источник Nasdaq GlobeNewswire

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

01 апр 2024 16:10:32 Источник Nasdaq GlobeNewswire

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

14 ноя 2023 07:00:54 Источник Nasdaq GlobeNewswire

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

08 ноя 2023 07:30:19 Источник Nasdaq GlobeNewswire

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

01 ноя 2023 07:30:41 Источник Nasdaq GlobeNewswire

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

06 сен 2023 07:30:14 Источник Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

11 авг 2023 07:00:22 Источник Nasdaq GlobeNewswire

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

14 июн 2023 07:30:22 Источник Nasdaq GlobeNewswire

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

09 май 2023 07:15:14 Источник Nasdaq GlobeNewswire

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

27 апр 2023 07:40:00 Источник Nasdaq GlobeNewswire

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

13 апр 2023 07:15:09 Источник Nasdaq GlobeNewswire

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

03 апр 2023 08:13:00 Источник Nasdaq GlobeNewswire